350 related articles for article (PubMed ID: 31562770)
21. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making.
Klonoff DC
J Diabetes Sci Technol; 2020 Jan; 14(1):174-179. PubMed ID: 30841738
[TBL] [Abstract][Full Text] [Related]
22. Through the looking glass: understanding non-inferiority.
Schumi J; Wittes JT
Trials; 2011 May; 12():106. PubMed ID: 21539749
[TBL] [Abstract][Full Text] [Related]
23. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
24. How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
Csoke E; Landes S; Francis MJ; Ma L; Teotico Pohlhaus D; Anquez-Traxler C
Clin Transl Sci; 2022 Jan; 15(1):43-54. PubMed ID: 34405554
[TBL] [Abstract][Full Text] [Related]
25. FDA oversight of cell therapy clinical trials.
Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
[TBL] [Abstract][Full Text] [Related]
26. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes.
O'Donnell JC; Le TK; Dobrin R; Higashi M; Pereira A; Wagner S; Yang A; Hukkelhoven M
Future Oncol; 2021 Jan; 17(3):333-347. PubMed ID: 33074018
[TBL] [Abstract][Full Text] [Related]
27. Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.
Burns L; Roux NL; Kalesnik-Orszulak R; Christian J; Hukkelhoven M; Rockhold F; O'Donnell J
Clin Ther; 2022 Mar; 44(3):420-437. PubMed ID: 35181179
[TBL] [Abstract][Full Text] [Related]
28. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs.
Zettler ME
Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688
[TBL] [Abstract][Full Text] [Related]
29. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
F1000Res; 2018; 7():111. PubMed ID: 30026923
[TBL] [Abstract][Full Text] [Related]
30. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
31. The Use of Real-World Evidence for Regulatory Decisions in China.
Xu J; Wu W; Zhang X; Ren Y; Yao M; Liu M; Zou K; Wang W; Sun X
Clin Pharmacol Ther; 2024 Jul; 116(1):82-95. PubMed ID: 38566457
[TBL] [Abstract][Full Text] [Related]
32. Hybrid clinical trials to generate real-world evidence: design considerations from a sponsor's perspective.
Zhu M; Sridhar S; Hollingsworth R; Chit A; Kimball T; Murmello K; Greenberg M; Gurunathan S; Chen J
Contemp Clin Trials; 2020 Jul; 94():105856. PubMed ID: 31669449
[TBL] [Abstract][Full Text] [Related]
33. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
[TBL] [Abstract][Full Text] [Related]
34. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
35. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
36. Evidence-based medicine and drug-eluting stents.
O'Dwyer J
Med Device Technol; 2004 May; 15(4):34-7. PubMed ID: 15303564
[TBL] [Abstract][Full Text] [Related]
37. Regulatory-grade clinical trial design using real-world data.
Levenson MS
Clin Trials; 2020 Aug; 17(4):377-382. PubMed ID: 32063037
[TBL] [Abstract][Full Text] [Related]
38. The Potential Effect of the 21st Century Cures Act on Drug Development.
Goble JA
J Manag Care Spec Pharm; 2018 Jul; 24(7):677-681. PubMed ID: 29952706
[TBL] [Abstract][Full Text] [Related]
39. Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?
Flynn R; Plueschke K; Quinten C; Strassmann V; Duijnhoven RG; Gordillo-Marañon M; Rueckbeil M; Cohet C; Kurz X
Clin Pharmacol Ther; 2022 Jan; 111(1):90-97. PubMed ID: 34689339
[TBL] [Abstract][Full Text] [Related]
40. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
